A phase II randomised study to evaluate the antitumour activity of roginolisib, a novel non-ATP competitive and allosteric modulator inhibiting PI3Kδ, in patients with metastatic uveal melanoma (OCULE-01).
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.tps9613
Abstract: TPS9613 Background: Uveal melanoma (UM) is a rare malignancy that develops from melanocytes in the eye. At least half of the patients develop metastases, primarily in the liver, and survival outcome from the time of… read more here.
Keywords: uveal melanoma; atp competitive; non atp; roginolisib ... See more keywords